Aug 2026· Cellular and Molecular Gastroenterology and Hepatology· pp.
101864
· 0 citations
Medicine
TL;DR
These findings suggest a highly conserved role for HDAC9 and class IIA HDACs in vertebrate pancreatic tumorigenesis and may lead to new strategies for reactivating (normal acinar/epithelial) differentiation programs to intercept and treat PDAC.
Abstract
Background
AND
Aims
While the majority of human pancreatic cancers are classified as pancreatic ductal adenocarcinomas (PDAC), tumors are comprised of diverse dedifferentiated tumor cell states that dynamically interact with an equally complex microenvironment, making it imperative to understand, in vivo, how normal epithelial identity is (dys)regulated during tumorigenesis.
Methods
Here, we integrate data from mouse and human PDAC with a unique zebrafish model of pancreatic cancer to elucidate evolutionarily conserved mechanisms regulating dedifferentiation during pancreatic tumorigenesis.
Results
Histological and single-cell transcriptional profiling of heterogeneous tumors developing in dual-transgenic ptf1a:Gal4-VP16; UAS:mKO2- KRASG12D adult zebrafish revealed mixed populations of progenitor-like cells with acinar features, progenitor-like cells with ductal features and undifferentiated progenitor-like cells, providing the opportunity to interrogate specific transcriptional and epigenetic modifiers controlling neoplastic pancreatic cellular differentiation. Screening a panel of chromatin modifiers and chromatin readers for differential expression in these distinct cell clusters revealed hdac9b to be upregulated in the progenitor-like cells enriched for ductal features. RNA velocity trajectories supported an acinar cell-of-origin for these hdac9b-expressing progenitor-like cells. Treatment of fish with the class IIA HDAC inhibitor TMP195 confirmed a functional role of HDAC activity in regulating neoplastic cell differentiation through repression of the ductal-like and progenitor cell states and associated re-activation of acinar gene expression (Graphical Abstract). Cross-species analyses in autochthonous murine tumors confirmed an early, evolutionarily conserved role for Hdac9 in pancreatic tumorigenesis, marking tumor cell subpopulations characterized by loss of epithelial differentiation and a basal subtype identity. In human pancreatic cancer, higher HDAC9 expression is significantly correlated with poorly differentiated tumor histology and predicts shorter overall survival in PDAC patients with classical subtype-enriched tumors.
Conclusions
These findings suggest a highly conserved role for HDAC9 and class IIA HDACs in vertebrate pancreatic tumorigenesis and may lead to new strategies for reactivating (normal acinar/epithelial) differentiation programs to intercept and treat PDAC.
There is broad consensus that the malignant epithelial cells of human pancreatic ductal adenocarcinoma (PDA) comprise multiple, molecularly distinct states. Yet precise characterization of how these are regulated-including their mechanistic determinants, dependencies, plasticity and functional properties-remains elusive. Single-cell master regulator (MR) analysis of multiple PDA cohorts identified malignant cells in three co-existing, molecularly distinct developmental lineage states, with distinct histopathological morphologies and spatial architecture. These include a poorly differentiated lineage driven by epithelial-mesenchymal-transition-related MRs and two well-differentiated states driven by gastrointestinal epithelial development and pancreatic development MRs, respectively. Furthermore, each state comprises two epigenetically distinct substates with low versus high MAPK signaling activity. Barcode-based lineage tracing confirmed both spontaneous and treatment-dependent cross-state plasticity. Furthermore, loss-of-function studies confirmed state-specific MR essentiality, while their ectopic expression effectively reprogrammed cell state, in vitro and in vivo, thus providing a mechanism-based foundation for PDA heterogeneity and a roadmap for pharmacological targeting.
P. Laise, Mikko M. Turunen, Álvaro Curiel-García et al.· Nature Genetics· 0 citations
Breast cancer is a heterogeneous disease in which a single oncogenic driver can give rise to divergent tumor phenotypes. How oncogenic mutations generate epithelial state plasticity and coordinately remodel the surrounding tissue remains incompletely understood. Here, we applied longitudinal single cell RNA-sequencing to trace the mammary landscape during Pik3caH1047R-driven tumor progression in the mouse. We identify an expansion of the epithelial transcriptional state space, in which luminal cells lose lineage fidelity and activate ciliated, basal, and squamous-like gene expression programs. While oncogene-expressing cells lose features of luminal identity, they retain expression of hormone-sensing genes such as Esr1, Pgr, and Foxa1. These transcriptional states are established early, and the transition to overt tumors is marked by the emergence of cancer-associated fibroblasts rather than new epithelial states. We identify a Postn+ fibroblast population enriched at the epithelial interface as a candidate progenitor of cancer-associated fibroblasts. Postn+ fibroblasts express an ECM-remodeling program and display altered epithelial crosstalk in oncogenic glands. Altogether, Pik3caH1047R activation initiates a tissue-level process beginning with epithelial lineage infidelity, followed by an altered stromal microenvironment, which together mark tumor initiation.
Jennifer T. Le, Eun K. Kim, Vasudha Srivastava et al.· bioRxiv· 0 citations
Lineage plasticity has emerged as a central mechanism through which cancer cells adapt to therapeutic pressure, evade immune surveillance, and acquire aggressive phenotypes. Although recognized across tumor types, the regulatory principles governing how cancer cells reprogram cellular identity remain incompletely understood. In this review, we propose that lineage plasticity in cancer reflects the redeployment of regulatory frameworks established during normal development. Rather than representing a stochastic byproduct of genomic instability, cancer plasticity frequently unfolds within gene regulatory architectures that also govern cell fate specification, lineage commitment, and controlled state transitions during embryogenesis and tissue homeostasis. Developmental transcription factors, including members of the SOX family, FOXA1, ASCL1, NKX2-1, and epithelial-mesenchymal transition regulators, function as lineage gatekeepers during development but are repurposed in cancer to destabilize lineage commitment and enable phenotypic switching. Similarly, epigenetic regulators that guide developmental trajectories, including chromatin remodeling complexes, Polycomb group proteins, and DNA methylation machinery, are frequently dysregulated or redistributed in tumors, altering the repression of lineage-stabilizing and alternative lineage programs and thereby weakening epigenetic barriers to lineage transitions. Together, these observations support a model in which development and cancer operate as mirror regulatory systems: one establishing and stabilizing cellular identity, the other exploiting the same regulatory architecture to permit adaptive reprogramming under selective pressure. We further discuss how emerging single-cell and spatial multi-omics technologies, integrated with artificial intelligence-based modeling, enable mapping of cell state landscapes and transitional trajectories, transforming lineage plasticity from a descriptive phenomenon into a measurable and predictable property of tumor evolution.
Melanie Fraidenburg, Longjun Li, Rosa Kwon et al.· Cancer Letters· 0 citations
Cancer cells possess unlimited proliferative potential, and the high expression of lncRNAs widely promotes cancer progression. Mammalian early embryos share similar characteristics, where numerous endogenous retroviruses become transcriptionally active during zygotic genome activation (ZGA). However, whether cancer-promoting lncRNAs can also facilitate early embryonic development remains unclear. In this study, we demonstrated that
TUG1
, which is highly expressed in tumors, regulates early embryonic development in mice.
TUG1
deficiency results in the arrest of mouse embryos at the two-cell stage, accompanied by disruption of the MAPK signaling pathway, and consequently leads to the failure of ZGA. Mechanistically, we uncover a
TUG1
-hnRNPA1 ribonucleoprotein complex that actively licenses ZGA by promoting the transcription of MAPK8, thereby activating the essential MAPK signaling pathway. This study transforms our understanding of
TUG1
from a cancer-specific effector to a critical regulator of the ZGA, raising the possibility that related regulatory principles may operate in other biological contexts.
Jianwu Wang, Guang Yang, Qingbo Yang et al.· Cellular and Molecular Life...· 0 citations
Inflammation in the pancreas drives acinar-to-ductal metaplasia (ADM), a progenitor-like state that can be hijacked by mutant Kras in the formation of pancreatic ductal adenocarcinoma. How these cell fate decisions vary according to KRAS mutation remains poorly understood. To define mutation-specific lineage reversion and tumor initiation, we implement Ptf1a-tdTomato mice and multiple KRAS mutants across several genetic, pharmacologic, and inflammatory perturbations in vivo. Whereas KRASG12D co-opts injury to enable lineage reversion, enhancer reprogramming, and tumor initiation, KRASG12R/V cannot sustain dedifferentiated and neoplastic transcriptional and epigenetic programs. Specifically, KRASG12R/V mutants fail to invoke robust EGFR, AKT, and RAC1/VAV1 signaling and to license Pou2f3 and Vav1 in chromatin, such that only constitutive AKT activation is sufficient to rescue the tumorigenic potential of KRASG12Rin vivo. As the marked heterogeneity among KRAS variants begins early in tumorigenesis, these data are crucial to deciphering mutation-specific oncogenic trajectories and directing the implementation of KRAS-directed therapeutics.
A. Grimont, David Falvo, W. Sisso et al.· Developmental Cell· 1 citation
Findings indicated a tumor-suppressing role of PBRM1 in PDAC, which constitutes a specific subgroup of patients with aggressive phenotype and prognostic significance.
Jin Li, Risheng Que, Jian Zhang et al.· Cancer Letters· 0 citations
